Haleon (NYSE:HLN) Rating Increased to Strong-Buy at UBS Group

UBS Group upgraded shares of Haleon (NYSE:HLN) to a strong-buy rating in a report published on Tuesday morning, Zacks.com reports.

A number of other equities analysts also recently issued reports on HLN. Morgan Stanley upped their price target on Haleon from $9.90 to $10.95 and gave the stock an overweight rating in a research report on Friday, September 20th. Berenberg Bank began coverage on shares of Haleon in a research report on Tuesday, August 6th. They set a buy rating for the company. Finally, The Goldman Sachs Group lowered shares of Haleon from a buy rating to a neutral rating in a report on Tuesday, August 6th. One research analyst has rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of Buy and an average target price of $10.95.

Haleon Stock Down 1.3 %

Shares of HLN stock opened at $10.40 on Tuesday. The company has a market capitalization of $47.49 billion, a price-to-earnings ratio of 34.67, a PEG ratio of 3.12 and a beta of 0.26. The company has a debt-to-equity ratio of 0.44, a current ratio of 0.84 and a quick ratio of 0.58. Haleon has a one year low of $7.70 and a one year high of $10.80. The company’s fifty day moving average price is $10.04 and its 200-day moving average price is $8.99.

Haleon (NYSE:HLN) last released its quarterly earnings results on Thursday, August 1st. The company reported $0.08 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.01). The firm had revenue of $3.50 billion for the quarter, compared to analysts’ expectations of $3.55 billion. Haleon had a net margin of 9.71% and a return on equity of 13.15%. During the same quarter in the prior year, the business earned $0.08 EPS. Sell-side analysts expect that Haleon will post 0.47 EPS for the current fiscal year.

Haleon Cuts Dividend

The company also recently announced a semi-annual dividend, which was paid on Thursday, September 19th. Shareholders of record on Friday, August 16th were given a $0.0514 dividend. This represents a yield of 1.6%. The ex-dividend date was Friday, August 16th. Haleon’s dividend payout ratio is currently 33.33%.

Institutional Trading of Haleon

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. AE Wealth Management LLC lifted its holdings in shares of Haleon by 6.1% in the 2nd quarter. AE Wealth Management LLC now owns 19,199 shares of the company’s stock valued at $159,000 after purchasing an additional 1,098 shares during the last quarter. Cardinal Capital Management lifted its position in Haleon by 2.5% during the second quarter. Cardinal Capital Management now owns 46,231 shares of the company’s stock worth $382,000 after buying an additional 1,140 shares during the period. Endowment Wealth Management Inc. raised its holdings in shares of Haleon by 9.9% during the 2nd quarter. Endowment Wealth Management Inc. now owns 12,867 shares of the company’s stock valued at $106,000 after buying an additional 1,161 shares during the period. Portside Wealth Group LLC lifted its holdings in Haleon by 2.7% in the 2nd quarter. Portside Wealth Group LLC now owns 44,985 shares of the company’s stock worth $372,000 after buying an additional 1,182 shares in the last quarter. Finally, Lester Murray Antman dba SimplyRich raised its holdings in Haleon by 2.9% in the second quarter. Lester Murray Antman dba SimplyRich now owns 45,519 shares of the company’s stock valued at $375,000 after acquiring an additional 1,301 shares in the last quarter. 6.67% of the stock is currently owned by institutional investors and hedge funds.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.